Daily Bulletin

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR Newswire APAC

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant...

Read more: US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG-PR...

Business News

Common Mistakes That Entrepreneurs Make (and Why They Can Derail Your Business)

Starting and running a business is no easy feat, even if you have exceptional training and experience. Fortunately, you can achieve your business goals by avoiding mistakes that can put your busines...

Daily Bulletin - avatar Daily Bulletin

What is a Union and Why It Matters for Workers' Rights

When asking, "What is a union?" the answer lies in understanding their crucial role in shaping the rights and conditions that workers enjoy today. From universal superannuation to the concept of the...

Daily Bulletin - avatar Daily Bulletin

How Does Climate Impact Shed Durability and Design Choices?

Climate plays a crucial role in determining the durability and design choices for sheds. The weather conditions in a specific area can significantly impact the longevity and performance of these str...

Daily Bulletin - avatar Daily Bulletin